-

04:13:10 AM

EVAX Stock News

EVAX - Evaxion Biotech A/S

06/03/23 5:00 PM

Nasdaq : EVAX

clinical trialAI

Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical responses were reported in 8 out of 12 EVX-01 treated patients High-quality neoantigens, predicted by AI technology, were associated with longer progression-free

RHEA-AI

very positive

05/31/23 8:30 AM

Nasdaq : EVAX

earnings

Evaxion Announces Business Update and First Quarter 2023 Financial Results

Full read-out of the Phase 1/2a trial of EVX-02 in 10 patients with completely resected melanoma was presented at AACR in April 2023, meeting primary endpoints and demonstrating relapse-free survival in all EVX-02 completers Recent R&D Day highlighted Evaxion´s proprietary genetic adjuvant

RHEA-AI

neutral

05/25/23 5:00 PM

Nasdaq : EVAX

Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines

Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccines Preclinically validated for both DNA and mRNA vaccines, and ready for clinical testing Anticipated large market potential for DNA and mRNA vaccines against cancer, viral and

RHEA-AI

neutral

05/25/23 5:00 PM

Nasdaq : EVAX

clinical trial

Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the

RHEA-AI

neutral

05/16/23 5:46 AM

Nasdaq : EVAX

conferences

Evaxion to host R&D Day on May 25, 2023

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, today announced that it will hold an R&D Day at 12:30 p.m CEST

RHEA-AI

neutral

04/27/23 7:00 AM

Nasdaq : EVAX

earnings

Fourth quarter and full year 2022 financial results and business update

Evaxion presented promising data from its Phase 1/2a clinical trial of EVX-02 in patients with late-stage melanoma at the 2023 AACR meeting EVX-03, a DNA-based personalized cancer vaccine, is expected to have a CTA filing in Q3 2023 and start a Phase 1 trial in solid tumor patients in Q4 2023

RHEA-AI

positive

04/18/23 8:00 AM

Nasdaq : EVAX

clinical trial

Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints

All 10 patients with late stage melanoma who completed EVX-02 treatment demonstrated robust and treatment-specific immune responses and were relapse-free at their last assessment Results further validate predictive potential of proprietary AI technology and pave the way for advancement of EVX-03, a

RHEA-AI

neutral

04/13/23 9:44 AM

Nasdaq : EVAX

clinical trial

Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful publication in Frontiers of Immunology of preclinical data demonstrating the effectiveness of its

RHEA-AI

neutral

03/28/23 7:46 AM

Nasdaq : EVAX

Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients

New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023 Phase 2b clinical trial reduced in size and expected to reach interim data on time (Q4 2023) Increased focus extends cash runway significantly COPENHAGEN, Denmark, March 28,

RHEA-AI

very positive

03/23/23 7:55 AM

Nasdaq : EVAX

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Evaxion Biotech A/S (NASDAQ: EVAX)

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

EVAX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.evaxion-biotech.com
Security nameEvaxion Biotech A/S - ADR
Issue typead
SectorManufacturing
Sic code2836
Employees61

About Evaxion Biotech A/S

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.